// App-Quantinova.ai

e15154 : Canadian experience managing dose intensity of regorafenib in relation to safety and clinical outcome in metastatic colorectal cancer patients.

Researchers

Presenter

  • Tasnia Hasan

Principal Investigators

  • Aline Mamo

  • Tomas Kavan

  • Young soo Rho

  • Petr Kavan

Medical Centers

  • Segal Cancer Center/Jewish General Hospital, McGill University, Montreal, QC, Canada

  • Department of Oncology, Faculty of Medicine, McGill University and Segal Cancer Centre - Jewish General Hospital, McGill University, Montreal, QC, Canada

  • Segal Cancer Center/Jewish General Hospital, McGill University, Montreal, QC, Canada

  • Montreal University, Montreal, QC, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Colorectal Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Regorafenib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved